23 octubre 2014
Few patients with recurrent or secondary cervical cancer have tumour shrinkage after conventional chemotherapy, and life expectancy is usually less than one year. An academic study into effects of cediranib drug in chemotherapy treatment of cervical cancer shows the drug to standard chemotherapy might be beneficial for patients with metastatic or recurrent cervical cancer.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/nCnDItthciI/141023193423.htm
